Company / SG&A Expense
ANI Pharmaceuticals, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$317.7M
FY2025
5-year range
$84.3M / $317.7M
FY2021-FY2025
Trend
+27.3%
vs FY2024
Sector context
#53 of 213
Health Care
What the data says
ANI Pharmaceuticals, Inc.'s sg&a expense of $318M is higher than 75% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 9 consecutive years, from $28M in FY2016 to $318M in FY2025.
Based on SEC 10-K filings.
$318M in FY2025 with a 5-year CAGR of +37.4%. Top quartile in the Health Care sector.
Increased from $162M to $318M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +36.8%
- 5-Year CAGR
- +37.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 213This company $317.7M Sector average $722.3M
▼
-56.0% below sector average
Key checks
Key Insights
- ANI Pharmaceuticals, Inc.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +37.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 27.3% year-over-year.
- Ranks #53 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $317.7M | +27.3% |
| FY2024 | $249.6M | +54.4% |
| FY2023 | $161.7M | +30.4% |
| FY2022 | $124.0M | +47.2% |
| FY2021 | $84.3M | +29.7% |
| FY2020 | $65.0M | +16.4% |
| FY2019 | $55.8M | +26.7% |
| FY2018 | $44.1M | +39.5% |
| FY2017 | $31.6M | +13.5% |
| FY2016 | $27.8M | +69.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026